COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict SIck Children)
Project Number3R33HD105619-03S1
Contact PI/Project LeaderKLEINMAN, LAWRENCE C Other PIs
Awardee OrganizationRUTGERS BIOMEDICAL AND HEALTH SCIENCES
Description
Abstract Text
The SARS-CoV-2 pandemic has manifested in children with a wide spectrum of clinical presentations ranging
from asymptomatic infection to devastating acute respiratory symptoms, appendicitis (often with rupture), and
Multisystem Inflammatory Syndrome in Children (MIS-C), a serious inflammatory condition presenting several
weeks after exposure to or infection with the virus. These presentations overlap in their clinical severity while
maintaining distinct clinical profiles. Public health and clinical approaches will benefit from an improved
understanding of the spectrum of illness associated with SARS CoV-2 and from the capacity to integrate data to
achieve two goals: (i) to identify the clinical, social, and biological variables that predict severe COVID-19 and
MIS-C, and (ii) to target those populations and individuals at greatest risk for harm from the virus. We propose
the COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness
in Children (CONNECT to Predict SIck Children) comprising eight partners providing access to data on >15
million children. Our network will systematically integrate social, epidemiological, genetic, immunological, and
computational approaches to identify both population- and individual-level risk factors for severe illness. Our
underlying hypothesis is that a combination of multidimensional data – clinical, sociodemographic, epidemiologic,
and biological -- can be integrated to predict which children are at greatest risk to have severe consequences
from SARS-CoV-2 infection. To test our hypothesis, we will develop CONNECT to Predict SIck Children, a
network of networks that leverages inpatient, outpatient, community, and epidemiological data resources to
support the analysis of large data using machine learning and model-based analyses. For the R61 phase, we
will develop and refine predictive models using data from our network of networks (Aim 1). We will also recruit
participants previously diagnosed with either COVID-19 or MIS-C (along with appropriate controls who have had
mild or asymptomatic infections with SARS-CoV2), who will provide survey data (including social determinants)
and saliva and blood samples to identify persisting biological factors associated with severe disease (Aim 2). We
will iteratively assess our models using a knowledge management framework that considers the marginal value
of data for improving models' predictive capacity over time. In the R33 phase, we will validate and further refine
predictive models incorporating data from additional participants recruited throughout our network of networks,
including newly infected children with severe COVID-19 or MIS-C identified through real-time surveillance (Aim
3). We seek to develop predictive models for children and adolescents that are useful, sensitive to community
and environmental contexts, and informed by the REASSURED framework specified by the RFA. The models
and biomarkers developed through our nationwide network of networks will produce generalizable knowledge
that will improve our ability to predict which children are at greatest risk for severe complications of SARS-CoV-
2 infection. This knowledge will facilitate interventions to prevent and treat severe pediatric illness.
Public Health Relevance Statement
PROJECT NARRATIVE
COVID-19, the disease caused by SARS-CoV-2, is a world-wide public health problem. Pediatric disease has
been particularly difficult to manage since children tend less frequently to get sick from SARS-CoV-2 infection
as adults but, when they do become ill, can present with life-threatening pulmonary disease or a systemic
inflammatory condition known as multisystem inflammatory syndrome. The proposed COVID-19 Network of
Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to
Predict SIck Children) will develop models and biomarkers that predict risk for severe disease in children and
adolescents by systematically integrating social science, epidemiological, genetic, biochemical, immunological,
and computational approaches.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2019-nCoVAcuteAcute DiseaseAdolescentAdultAffectAppendicitisBiochemicalBiologicalBiological FactorsBiological MarkersBlood specimenCOVID-19COVID-19 pandemicCharacteristicsChildChildhoodChronicClinicalClinical DataCommunitiesDataDiagnosisDiagnosticDiseaseEnvironmental Risk FactorEpidemiologyExposure toFundingGeneticGenetic PolymorphismGoalsHealth Information SystemHealthcareHeart DiseasesImmune responseImmunologicsIndividualInfectionInflammatoryInformation SystemsInpatientsInterventionKnowledgeKnowledge ManagementLifeLung diseasesMachine LearningMaternal and Child HealthMeasurementModelingMorbidity - disease rateMultisystem Inflammatory Syndrome in ChildrenObesityOutpatientsPathogenicityPatient RecruitmentsPediatric HospitalsPhasePopulationPublic HealthRADxRare DiseasesReportingResearchRespiratory Signs and SymptomsRheumatologyRiskRisk FactorsRuptureSARS-CoV-2 infectionSeriesSeveritiesSocial SciencesSpecific qualifier valueSurveysSymptomsSyndromeSystemTestingTimeUnited States Health Resources and Services AdministrationVirusYouthcase findingcoronavirus diseasedata integrationdata resourcedevelopmental diseaseepidemiologic dataimprovedinfection riskmortalitymultidimensional datapredictive markerpredictive modelingpreventrisk predictionsaliva samplesevere COVID-19socialsocial determinantssociodemographicstranslational approach
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
310
DUNS Number
090299830
UEI
YVVTQD8CJC79
Project Start Date
01-January-2021
Project End Date
30-November-2025
Budget Start Date
01-June-2023
Budget End Date
30-November-2025
Project Funding Information for 2023
Total Funding
$1,517,692
Direct Costs
$1,175,018
Indirect Costs
$342,674
Year
Funding IC
FY Total Cost by IC
2023
NIH Office of the Director
$1,517,692
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R33HD105619-03S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R33HD105619-03S1
Patents
No Patents information available for 3R33HD105619-03S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R33HD105619-03S1
Clinical Studies
No Clinical Studies information available for 3R33HD105619-03S1
News and More
Related News Releases
No news release information available for 3R33HD105619-03S1
History
No Historical information available for 3R33HD105619-03S1
Similar Projects
No Similar Projects information available for 3R33HD105619-03S1